| Dealing With Variable Drug Exposure Due to Variable Hepatic Metabolism: A Proof‐of‐Concept Application of Liquid Biopsy in Renal Impairment A Rostami‐Hodjegan, ZM Al‐Majdoub, Y von Grabowiecki, KL Yee, ... Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
| This is no longer just about liver: LC-MS proteomics for organ exposure brain/kidney/gut/skin/placenta Z Al-Majdoub Drug Metabolism and Pharmacokinetics 55, 100564, 2024 | | 2024 |
| Quantitative Proteomics for Translational Pharmacology and Precision Medicine: State of The Art and Future Outlook B Prasad, ZM Al-Majdoub, C Wegler, A Rostami-Hodjegan, B Achour Drug Metabolism and Disposition, 2024 | | 2024 |
| Complementarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transporters in human liver AM Vasilogianni, S Alrubia, E El-Khateeb, ZM Al-Majdoub, N Couto, ... Molecular Omics 20 (2), 115-127, 2024 | | 2024 |
| Toward systems-informed models for biologics disposition: covariates of the abundance of the neonatal Fc receptor (FcRn) in human tissues and implications for pharmacokinetic … J Barber, ZM Al-Majdoub, N Couto, M Howard, Y Elmorsi, D Scotcher, ... European Journal of Pharmaceutical Sciences 182, 106375, 2023 | 5 | 2023 |
| Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis AM Vasilogianni, ZM Al-Majdoub, B Achour, SA Peters, ... Frontiers in Oncology 13, 1010563, 2023 | | 2023 |
| Quantitative Assessment of the Impact of Crohn's Disease on Protein Abundance of Human Intestinal Drug-Metabolising Enzymes and Transporters S Alrubia, ZM Al-Majdoub, B Achour, A Rostami-Hodjegan, J Barber Journal of Pharmaceutical Sciences 111 (10), 2917-2929, 2022 | 10 | 2022 |
| Quantitative proteomics of hepatic drug‐metabolizing enzymes and transporters in patients with colorectal cancer metastasis AM Vasilogianni, ZM Al‐Majdoub, B Achour, S Annie Peters, J Barber, ... Clinical Pharmacology & Therapeutics 112 (3), 699-710, 2022 | 8 | 2022 |
| Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5′-Diphosphate … AN Ahmed, A Rostami-Hodjegan, J Barber, ZM Al-Majdoub Drug Metabolism and Disposition 50 (8), 1119-1125, 2022 | 5 | 2022 |
| Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease AM Vasilogianni, E El-Khateeb, ZM Al-Majdoub, S Alrubia, ... Journal of Proteomics 263, 104601, 2022 | 9 | 2022 |
| A family of QconCATs (Quantification conCATemers) for the quantification of human pharmacological target proteins AM Vasilogianni, E El-Khateeb, B Achour, S Alrubia, A Rostami-Hodjegan, ... Journal of Proteomics 261, 104572, 2022 | 5 | 2022 |
| Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients with Colorectal Cancer Liver Metastasis A Vasilogianni, Z Al-Majdoub, B Achour, S Peters, J Barber, ... EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 78 (SUPPL 1), S6-S6, 2022 | | 2022 |
| Label-free but still constrained: assessment of global proteomic strategies for the quantification of hepatic enzymes and transporters J Barber, ZM Al-Majdoub, N Couto, AM Vasilogianni, A Tillmann, ... Drug Metabolism and Disposition 50 (6), 762-769, 2022 | 3 | 2022 |
| Liquid biopsy for patient characterization in cardiovascular disease: verification against markers of cytochrome P450 and P‐glycoprotein activities B Achour, P Gosselin, J Terrier, Y Gloor, ZM Al‐Majdoub, TM Polasek, ... Clinical Pharmacology & Therapeutics 111 (6), 1268-1277, 2022 | 24 | 2022 |
| Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects AM Vasilogianni, ZM Al‐Majdoub, B Achour, SA Peters, ... British Journal of Clinical Pharmacology 88 (4), 1811-1823, 2022 | 16 | 2022 |
| In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition Y Murata, S Neuhoff, A Rostami-Hodjegan, H Takita, ZM Al-Majdoub, ... The AAPS journal 24 (1), 28, 2022 | 15 | 2022 |
| Quantitative proteomic map of enzymes and transporters in the human kidney: stepping closer to mechanistic kidney models to define local kinetics ZM Al‐Majdoub, D Scotcher, B Achour, J Barber, A Galetin, ... Clinical Pharmacology & Therapeutics 110 (5), 1389-1400, 2021 | 17 | 2021 |
| Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment E El-Khateeb, B Achour, ZM Al-Majdoub, J Barber, A Rostami-Hodjegan Molecular Pharmaceutics 18 (9), 3563-3577, 2021 | 43 | 2021 |
| Proteomic quantification of changes in abundance of drug-metabolizing enzymes and drug transporters in human liver cirrhosis: different methods, similar outcomes E El-Khateeb, ZM Al-Majdoub, A Rostami-Hodjegan, J Barber, B Achour Drug Metabolism and Disposition 49 (8), 610-618, 2021 | 19 | 2021 |
| Hepatic scaling factors for in vitro–in vivo extrapolation of metabolic drug clearance in patients with colorectal cancer with liver metastasis AM Vasilogianni, B Achour, D Scotcher, SA Peters, ZM Al-Majdoub, ... Drug Metabolism and Disposition 49 (7), 563-571, 2021 | 12 | 2021 |
Amin Rostami-HodjeganProfessor of Systems Pharmacology, University of Manchester, UKVerified email at manchester.ac.uk
